| pubmed-article:12467634 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12467634 | lifeskim:mentions | umls-concept:C0010658 | lld:lifeskim |
| pubmed-article:12467634 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:12467634 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:12467634 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:12467634 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12467634 | pubmed:dateCreated | 2002-12-6 | lld:pubmed |
| pubmed-article:12467634 | pubmed:abstractText | A new class of inhibitors for cysteine proteases cathepsin B, L, K and S is described. These inhibitors are based on the beta-lactam ring designed to interact with the nucleophilic thiol of the cysteine in the active site of cysteine proteases. Some 3-acylamino-azetidin-2-one derivatives showed very potent inhibition activities for cathepsins L, K and S at the nanomolar or subnanomolar IC(50) values. | lld:pubmed |
| pubmed-article:12467634 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12467634 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12467634 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12467634 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:12467634 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:ThomasGeorgeG | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:KaletaJadwiga... | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:ZhouNian ENE | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:GuoDeqiD | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:PurisimaEnric... | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:MenardRobertR | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:MicetichRonal... | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:SinghRajeshwa... | lld:pubmed |
| pubmed-article:12467634 | pubmed:author | pubmed-author:ReddyAndhe... | lld:pubmed |
| pubmed-article:12467634 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12467634 | pubmed:day | 6 | lld:pubmed |
| pubmed-article:12467634 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:12467634 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12467634 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12467634 | pubmed:pagination | 139-41 | lld:pubmed |
| pubmed-article:12467634 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:meshHeading | pubmed-meshheading:12467634... | lld:pubmed |
| pubmed-article:12467634 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12467634 | pubmed:articleTitle | 3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors. | lld:pubmed |
| pubmed-article:12467634 | pubmed:affiliation | SynPhar Laboratories, currently NAEJA Pharmaceutical Inc., 4290-91A Street, Edmonton, Alberta, Canada T6E 5V2. | lld:pubmed |
| pubmed-article:12467634 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:12467634 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12467634 | lld:pubmed |
